ONTARIO OSTEOPOROSIS STRATEGY Ontario Osteoporosis Strategy The Ontario Osteoporosis Strategy represents the vision and coordinated efforts of many groups, including the Ministry of Health and Long-Term Care (MOHLTC), Ontario Women’s […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Latest News Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture April 3, 2024 Amgen Canada has […]

In 2008 the results of a small study were published reporting on the use of choline stabilized orthosilicic acid a form of silicon, or placebo in 184 women with low […]

New survey reveals Canadians are largely unaware about osteoporosis and the serious consequences it can have on their health TORONTO, ON (February 2, 2016) – Snow and ice can make walking […]

SERMS Selective Estrogen Receptor Modulators Raloxifene (Evista®) is from a family of drugs called SERMs (Selective Estrogen Receptor Modulators). How Does Raloxifene Work? During their reproductive years, women produce significant […]

In a study published on Oct 28, 2014 by Dr. Michaelsson of Uppsala University, Sweden in the BMJ, high milk intake was associated with an increased rate of death in […]

A recent study from the US suggests women who drink as little as one cup /250 ml of cow’s milk per day could be increasing their risk of developing breast […]